Breaking News

Financial Report: Bristol-Myers Squibb

January 24, 2013

Avapro, Plavix patent expirations hurt results

Bristol-Myers Squibb
4Q Revenues: $4.2 billion (-23%)

4Q Earnings: $924 million (-25%)

YTD Revenues: $17.6 billion (-17%)

YTD Earnings: $2.5 billion (-52%)

Comments: U.S. sales decreased 38% to $2.2 billion in the quarter due to patent expirations for Avapro/Avalide in March 2012 and Plavix in May 2012. International sales were up 6% to $2.0 billion. Plavix sales were down 97% to $49 million. Avapro/Avalide sales were down 57% to $84 million. Abilify sales were up 11% to $819 million. Sprycel sales were up 24% to $281 million. Yervoy sales were up 47% to $211 million. Orencia sales were up 26% to $325 million. Onglyza/Kombiglyze sales were $198 million, up 29%. R&D expenses increased 7% to $1.1 billion in the quarter.
blog comments powered by Disqus
  • Staying Ahead in the Small Molecule Space

    Staying Ahead in the Small Molecule Space

    Dr. Matthew Moorcroft, VP Global Marketing, Cambrex||September 8, 2016
    Understand what is happening in the market and react accordingly

  • FDA & Drug Development

    FDA & Drug Development

    Rachelle Du2019Souza, Regulatory Heights Inc.||September 8, 2016
    You must perform the necessary due diligence to stay on top of regulatory developments

  • Patent Law  and Contract Manufacturing

    Patent Law and Contract Manufacturing

    Beverly W. Lubit, Member of the Firm, Chiesa Shahinian & Giantomasi||September 8, 2016
    Analyzing the impact of The Medicines Co. vs. Hospira Inc. decision